Suicide stunner prompts Amgen to dump brodalumab for psoriasis, walk away from AstraZeneca

John Carroll FierceBiotech News

Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

Damian Garde The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might ...

AstraZeneca partner Ardelyx dives (again) as lead drug flunks PhII

John Carroll FierceBiotech News

AstraZeneca struggles to spin out anti-infectives division, coming down to the wire

John Carroll The moment of truth is arriving for AstraZeneca's anti-infectives unit. For more than a year now, the pharma giant has been quietly shopping a deal, seeking an investor ...

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

Carly Helfand AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal. FiercePharma ...

AstraZeneca earmarks $200M to support its burgeoning biologics pipeline

Damian Garde Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $ 200 million to build ...

AstraZeneca trumpets a preclinical long shot in bid to burnish Brilinta’s prospects

John Carroll It's not often that a Big Pharma company puts out a press release announcing the launch of a preclinical drug program. The mortality rate of therapies that have yet ...

Nexium reprieve lets AstraZeneca spend, spend, spend to prep for 2015 knockdown

Tracy Staton AstraZeneca hiked its 2014 forecast for the second time this year. Sales were up by 5%. Instead of apologizing for a lack of growth, CEO Pascal Soriot could crow about ...

Almirall sends 719 employees to AstraZeneca as part of respiratory deal

Emily Wasserman AstraZeneca signed on the dotted line for Almirall, gaining access to the company's promising respiratory drug portfolio and products currently under development. ...

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

John Carroll FierceBiotech News

AstraZeneca seals the deal for Almirall’s respiratory meds

Emily Wasserman With generic and branded rivals inching up on AstraZeneca's blockbuster respiratory drug Symbicort, the pharma giant has a game plan locked, loaded and ready to ...

Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues

Eric Palmer Ranbaxy Laboratories in June finally managed to finesse its regulatory problems enough to get a generic of Novartis' Diovan to market, boosting its own fortunes while ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS